Covaxin approval is a giant leap for innovation: Bharat Biotech MD
By MYBRANDBOOK
The approval of COVAXIN for emergency use is a giant leap for innovation and novel product development in India, Krishna Ella, Chairman and Managing Director of Bharat Biotech, said.
DCGI-Central Standards Control Organization gave a green signal for the emergency use of its Covid-19 vaccine. Expressing his delight on the approval, the CMD of vaccine maker said, "It is a proud moment for the nation and a great milestone in India's scientific capability. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist.
"The development of COVAXIN was based on a public-private partnership between ICMR, NIV and Bharat Biotech. We thank Director-General ICMR Balram Bhargava for his leadership in this project," he said.
The Subject Expert Committee of Central Drugs Standards Control Organization made the recommendations for the Drugs Controller General of India's final decision.
Developed in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), COVAXIN is indigenous, inactivated vaccine developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.
The evaluation of COVAXIN has resulted in several unique product characteristics, including long term persistence of immune responses to multiple viral proteins instead of only the spike protein. It demonstrated broad-spectrum neutralizing capability with heterologous SARS-CoV2 strains, thus potentially reducing or eliminating escape mutants. It critical characteristic is the demonstrated safety profile, which is significantly lower than several other vaccines with published data.
Thus far, the product development and clinical trial data have generated five publications, 4 of which have been accepted and published soon. The publication of phase II trial data is undergoing the peer review process. As a part of our regulatory guidelines, all data has been submitted to the DCGI and CDSCO.
Bharat Biotech has 140 global patents and a product portfolio of more than 16 vaccines, four bio-therapeutics, registrations in more than 116 countries and WHO Pre-qualifications.
The company has delivered over 4 billion doses of vaccines worldwide and continues to lead innovation. It has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world's first tetanus-toxoid conjugated vaccine for Typhoid.
BREAKING NEWS
TECHNO TRENDS
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
E-Magazine
TECHNOTAINMENT
Hrithik Roshan to endorse RuPay as Brand Ambassador
RuPay is reportedly planning to feature Bollywood superstar Hrithik Rosha
India Today Group launches – AI Pop Stars
Staying true to our industry leadership position in using cutting-edge tech
MOVERS & SHAKERS
TelioLabs ropes in Phaniraj V A as the Group CEO
TelioLabs has announced the onboarding of Phaniraj V A as its new Group CE
Wipro Appoints Amit Kumar as Managing Partner and Global Head
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology s
OPEN YOUR EYES
INTERVIEWS
Delivering Critical Business Communication Solutions to Enterp
Arya Omnitalk and Syntel’s comprehensive suite of solutions and more than
Autodesk continually pushing the boundaries in the Design and
Autodesk’s vision is of a better world designed and made for all. It inte
HOT PICK
MSI Announces the availability of RTX 50 series of laptops in
MSI, the innovative computing manufacturer in gaming, creator
Nothing Phone (3a) goes on sale today, starting at Rs 19,999
The phone was launched on March 4, featuring a 50MP main, ultra-wide, and t
MAKE IN INDIA BRANDS
TALLY SOLUTIONS PVT. LTD.
SAMRIDDHI AUTOMATIONS PVT. LTD.
BPE INDIA PVT. LTD.
HAVELLS INDIA LTD.
EMINENT CIO'S OF INDIA
ICONS OF INDIA
Icons Of India : AMIT CHADHA
Amit Chadha serves as the CEO and Managing Director of L&T Technology ...
Icons Of India : Harsh Jain
Harsh Jain, the co-founder of Dream 11, the largest fantasy sports web...
Icons Of India : NANDAN NILEKANI
Nandan Nilekani is the Co-Founder and Chairman of Infosys Technologies...
PARTNER SPEAKERS
PSU
GSTN - Goods and Services Tax Network
GSTN provides shared IT infrastructure and service to both central and...
C-DOT - Center of Development of Telematics
India’s premier research and development center focused on telecommu...
CSC - Common Service Centres
CSC initiative in India is a strategic cornerstone of the Digital Indi...
VIDEOS
Top 25 Brands
Global Indian industry
Indian Tech Talent Excelling The Tech World - NEAL MOHAN, CEO - Youtube
Neal Mohan, the CEO of YouTube, has a bold vision for the platform’s...
Indian Tech Talent Excelling The Tech World - PADMASREE WARRIOR, Founder, President & CEO - Fable
Padmasree Warrior, the Founder, President, and CEO of Fable, is revolu...
Indian Tech Talent Excelling The Tech World - Vinod Dham, Founder & Executive Managing Partner, IndoUS Venture Partners
Vinod Dham, known as the “Father of the Pentium Chip,” has left an...
ITFORUM 2025
CMO of the Year
WOMEN LEADERSHIP
IMAGE GALLERY
TRENDS IN TECHNOLOGY
MORE VIDEOS
ADVERTISEMENTS
TECHNOLOGY DISRUPTION
UNICORNS REVOLUTIONISING
of images belongs to the respective copyright holders
